keyword
MENU ▼
Read by QxMD icon Read
search

Bevacizumab glioblastoma

keyword
https://www.readbyqxmd.com/read/28819189/vascular-hysteresis-loops-and-vascular-architecture-mapping-in-patients-with-glioblastoma-treated-with-antiangiogenic-therapy
#1
Andreas Stadlbauer, Max Zimmermann, Stefan Oberndorfer, Arnd Doerfler, Michael Buchfelder, Gertraud Heinz, Karl Roessler
In this study, we investigated the variability of vascular hysteresis loop (VHL) shapes and the spatial heterogeneity of neovascularization and microvascular alterations using vascular architecture mapping (VAM) in patients with recurrent glioblastoma during bevacizumab mono-therapy. VAM data were acquired in 13 patients suffering from recurrent glioblastoma prior to and 3 months after bevacizumab treatment onset using a dual contrast agent injections approach as part of routine MRI. Two patients were additionally examined after the first cycle of bevacizumab to check for early treatment response...
August 17, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28812437/autophagy-induced-kdr-vegfr-2-activation-promotes-the-formation-of-vasculogenic-mimicry-by-glioma-stem-cells
#2
Hai-Bo Wu, Shuai Yang, Hai-Yan Weng, Qian Chen, Xi-Long Zhao, Wen-Juan Fu, Qin Niu, Yi-Fang Ping, Ji Ming Wang, Xia Zhang, Xiao-Hong Yao, Xiu-Wu Bian
Antiangiogenesis with bevacizumab, an antibody against vascular endothelial growth factor (VEGF), has been used for devascularization to limit the growth of malignant glioma. However, the benefits are transient due to elusive mechanisms underlying resistance to the antiangiogenic therapy. Glioma stem cells (GSCs) are capable of forming vasculogenic mimicry (VM), an alternative microvascular circulation independent of VEGF-driven angiogenesis. Herein, we report that the formation of VM was promoted by bevacizumab-induced macroautophagy/autophagy in GSCs, which was associated with tumor resistance to antiangiogenic therapy...
August 16, 2017: Autophagy
https://www.readbyqxmd.com/read/28808777/phase-ii-study-of-bi-weekly-temozolomide-plus-bevacizumab-for-adult-patients-with-recurrent-glioblastoma
#3
Michael A Badruddoja, Marjorie Pazzi, Abhay Sanan, Kurt Schroeder, Kevin Kuzma, Thomas Norton, Thomas Scully, Daruka Mahadevan, Michael Malek Ahmadi
PURPOSE: Bevacizumab is an active anti-angiogenic agent in the treatment of recurrent glioblastoma. Temozolomide can prolong survival in patients with newly diagnosed glioblastoma. At recurrence, alternate dosing of temozolomide has shown to further deplete methyl-guanine-methyltransferase (MGMT) conferring added activity for patients who have progressed on the standard dosing regimen. In this study, bevacizumab plus biweekly temozolomide was evaluated for efficacy in adult patients with recurrent glioblastoma...
August 14, 2017: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/28797031/regulation-of-hypoxia-induced-autophagy-in-glioblastoma-involves-atg9a
#4
Siti Aminah Abdul Rahim, Anne Dirkse, Anais Oudin, Anne Schuster, Jill Bohler, Vanessa Barthelemy, Arnaud Muller, Laurent Vallar, Bassam Janji, Anna Golebiewska, Simone P Niclou
BACKGROUND: Hypoxia is negatively associated with glioblastoma (GBM) patient survival and contributes to tumour resistance. Anti-angiogenic therapy in GBM further increases hypoxia and activates survival pathways. The aim of this study was to determine the role of hypoxia-induced autophagy in GBM. METHODS: Pharmacological inhibition of autophagy was applied in combination with bevacizumab in GBM patient-derived xenografts (PDXs). Sensitivity towards inhibitors was further tested in vitro under normoxia and hypoxia, followed by transcriptomic analysis...
August 10, 2017: British Journal of Cancer
https://www.readbyqxmd.com/read/28792121/female-sex-good-performance-status-and-bevacizumab-induced-hypertension-associated-with-survival-benefit-in-asian-patients-with-recurrent-glioblastoma-treated-with-bevacizumab
#5
Chi-Ting Liau, Wen-Chi Chou, Kuo-Chen Wei, Chen-Nen Chang, Cheng-Hong Toh, Shih-Ming Jung
AIM: The goals of this study were to assess the activity and safety profile of bevacizumab in Taiwan Chinese patients with recurrent glioblastoma, to determine whether their response differed from that reported in other clinical trials, and to examine potential prognostic factors for survival. METHODS: We retrospectively assessed patients who received bevacizumab for recurrent glioblastoma between 2012 and 2015. Twelve predefined variables and the outcomes of our cohort were analyzed...
August 9, 2017: Asia-Pacific Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28761758/the-european-society-for-medical-oncology-magnitude-of-clinical-benefit-scale-field-tested-in-infrequent-tumour-entities-an-extended-analysis-of-its-feasibility-at-the-medical-university-of-vienna
#6
Barbara Kiesewetter, Markus Raderer, Gerald W Prager, Thorsten Fuereder, Christine Marosi, Matthias Preusser, Michael Krainer, Gottfried J Locker, Thomas Brodowicz, Christoph C Zielinski
BACKGROUND: The European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) is a new tool to quantify the clinical benefit that may be anticipated from a novel anticancer treatment. We present here an analysis on the feasibility of the ESMO-MCBS in less frequent tumour entities. METHODS: This study evaluates the practicability of the ESMO-MCBS for metastatic neuroendocrine tumours (NETs), soft tissue sarcomas, glioblastoma, thyroid cancer, pancreatic cancer, head/neck cancer, urothelial cancer and ovarian cancer at the Medical University Vienna...
2017: ESMO Open
https://www.readbyqxmd.com/read/28744320/quantification-of-tumor-vascular-permeability-and-blood-volume-by-positron-emission-tomography
#7
Haojun Chen, Xiao Tong, Lixin Lang, Orit Jacobson, Bryant C Yung, Xiangyu Yang, Ruiliang Bai, Dale O Kiesewetter, Ying Ma, Hua Wu, Gang Niu, Xiaoyuan Chen
Purpose: Evans Blue (EB) is an azo dye that binds quantitatively with serum albumin. With an albumin binding, NOTA conjugated truncated Evan's blue (NEB) dye derived PET tracer, we aimed to establish a strategy for evaluating vascular permeability in malignant tumors via non-invasive PET. Experimental design: Sixty-minute dynamic PET using [(18)F]FAl-NEB was performed in three xenograft tumor models including INS-1 rat insulinoma, UM-SCC-22B human head and neck carcinoma and U-87 MG human glioblastoma. Tumor vascular permeability was quantified by the difference of the slopes between tumor and blood time-activity curve (TACs, expressed as Ps )...
2017: Theranostics
https://www.readbyqxmd.com/read/28739720/inhibition-of-bevacizumab-induced-epithelial-mesenchymal-transition-by-batf2-overexpression-involves-the-suppression-of-wnt-%C3%AE-catenin-signaling-in-glioblastoma-cells
#8
Wenqiu Huang, Chenguang Zhang, Mengtian Cui, Jing Niu, Wei Ding
BACKGROUND/AIM: Bevacizumab (BV) has been used for the treatment of recurrent glioblastoma. However, it also induces epithelial-mesenchymal transition (EMT) in glioblastoma cells, which compromises its efficacy. BATF2 (basic leucine zipper ATF-like transcription factor 2), a multi-target transcriptional repressor, has been found to suppress cancer development partly through inhibition of Wnt/β-catenin singling. The roles of BATF2 and Wnt/β-catenin signaling in BV-induced EMT in glioblastoma cells were investigated in this study...
August 2017: Anticancer Research
https://www.readbyqxmd.com/read/28726173/recurrent-glioblastomas-in-the-elderly-after-maximal-first-line-treatment-does-preserved-overall-condition-warrant-a-maximal-second-line-treatment
#9
Marc Zanello, Alexandre Roux, Renata Ursu, Sophie Peeters, Luc Bauchet, Georges Noel, Jacques Guyotat, Pierre-Jean Le Reste, Thierry Faillot, Fabien Litre, Nicolas Desse, Evelyne Emery, Antoine Petit, Johann Peltier, Jimmy Voirin, François Caire, Jean-Luc Barat, Jean-Rodolphe Vignes, Philippe Menei, Olivier Langlois, Edouard Dezamis, Antoine Carpentier, Phong Dam Hieu, Philippe Metellus, Johan Pallud
A growing literature supports maximal safe resection followed by standard combined chemoradiotherapy (i.e. maximal first-line therapy) for selected elderly glioblastoma patients. To assess the prognostic factors from recurrence in elderly glioblastoma patients treated by maximal safe resection followed by standard combined chemoradiotherapy as first-line therapy. Multicentric retrospective analysis comparing the prognosis and optimal oncological management of recurrent glioblastomas between 660 adult patients aged of < 70 years (standard group) and 117 patients aged of ≥70 years (elderly group) harboring a supratentorial glioblastoma treated by maximal first-line therapy...
July 19, 2017: Journal of Neuro-oncology
https://www.readbyqxmd.com/read/28711289/clinical-outcomes-in-recurrent-glioblastoma-with-bevacizumab-therapy-an-analysis-of-the-literature
#10
REVIEW
Matthew Tipping, Jens Eickhoff, H Ian Robins
Bevacizumab (BEV) is a common treatment for recurrent glioblastoma (GBM). After progression on BEV, there is no consensus on subsequent therapy, as multiple chemotherapy trials have failed to demonstrate discernible activity for salvage. A previous review (995 patients) estimated a progression free survival (PFS) on BEV of 4.2months (SD±2.1) with an overall survival (OS) after progression on BEV at 3.8months (SD±1). We endeavored to establish a more rigorous historical control, both as a benchmark for efficacy, and a prognostic tool for clinical practice...
July 12, 2017: Journal of Clinical Neuroscience: Official Journal of the Neurosurgical Society of Australasia
https://www.readbyqxmd.com/read/28702781/radiographic-patterns-of-progression-with-associated-outcomes-after-bevacizumab-therapy-in-glioblastoma-patients
#11
David Cachia, Nabil A Elshafeey, Carlos Kamiya-Matsuoka, Masumeh Hatami, Kristin D Alfaro-Munoz, Jacob J Mandel, Rivka Colen, John F DeGroot
Treatment response and survival after bevacizumab failure remains poor in patients with glioblastoma. Several recent publications examining glioblastoma patients treated with bevacizumab have described specific radiographic patterns of disease progression as correlating with outcome. This study aims to scrutinize these previously reported radiographic prognostic models in an independent data set to inspect their reproducibility and potential for clinical utility. Sixty four patients treated at MD Anderson matched predetermined inclusion criteria...
July 12, 2017: Journal of Neuro-oncology
https://www.readbyqxmd.com/read/28698441/-combination-therapy-with-radiation-temozolomide-and-bevacizumab-after-partial-tumor-removal-in-glioblastoma-patients-with-low-performance-status
#12
Junzo Nakao, Eiichi Ishikawa, Masahide Matsuda, Tetsuya Yamamoto, Shingo Takano, Akira Matsumura
INTRODUCTION: It is unclear whether or not bevacizumab(Bev)has a curative ability in newly diagnosed glioblastoma(GBM) patients with low Karnofsky performance status(KPS). MATERIALS AND METHODS: Four of 14 patients with newly diagnosed GBM received combination therapy with extended local radiation, temozolomide(TMZ), and Bev after partialremovalor biopsy of the tumor. RESULTS: The average patient age was 77.2 years(range 67-85)and the male-to-female ratio was 1:3...
June 2017: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/28693286/bevacizumab-as-a-last-line-treatment-for-glioblastoma-following-failure-of-radiotherapy-temozolomide-and-lomustine
#13
Katharina J Wenger, Marlies Wagner, Se-Jong You, Kea Franz, Patrick N Harter, Michael C Burger, Martin Voss, Michael W Ronellenfitsch, Emmanouil Fokas, Joachim P Steinbach, Oliver Bähr
In previous trials, bevacizumab failed to prolong the overall survival time in newly diagnosed glioblastoma and at the first recurrence. Randomized clinical trials at the second or further recurrence following the failure of radiotherapy, temozolomide and lomustine, and retrospective analyses focusing on this specific cohort, are not yet available. A total of 62 patients with glioblastoma who received bevacizumab after the failure of standard care, including radiotherapy, temozolomide and lomustine, were retrospectively identified...
July 2017: Oncology Letters
https://www.readbyqxmd.com/read/28678747/targeting-intercellular-adhesion-molecule-1-prolongs-survival-in-mice-bearing-bevacizumab-resistant-glioblastoma
#14
Yuji Piao, Verlene Henry, Ningyi Tiao, Soon Young Park, Juan Martinez-Ledesma, Jian Wen Dong, Veerakumar Balasubramaniyan, John F de Groot
Intercellular cell adhesion molecule 1 (ICAM-1; also known as CD54) is overexpressed in bevacizumab-resistant glioblastoma. In the present study, we tested our hypothesis that highly expressed ICAM-1 mediates glioblastoma's resistance to antiangiogenic therapy. We validated ICAM-1 overexpression in tumors resistant to antiangiogenic therapy using real-time polymerase chain reaction, immunohistochemistry, and Western blotting. We also detected ICAM1 expression in most glioma stem cells (GSCs). We investigated the mechanism of ICAM-1 overexpression after bevacizumab treatment and found that ICAM-1 protein expression was markedly increased in a time-dependent manner in GSC11 and GSC17 cells under hypoxic conditions in vitro...
June 29, 2017: Oncotarget
https://www.readbyqxmd.com/read/28678383/the-role-of-early-magnetic-resonance-imaging-in-predicting-survival-on-bevacizumab-for-recurrent-glioblastoma-results-from-a-prospective-clinical-trial-cabaret
#15
Kathryn M Field, Pramit M Phal, Greg Fitt, Christine Goh, Anna K Nowak, Mark A Rosenthal, John Simes, Elizabeth H Barnes, Kate Sawkins, Lawrence M Cher, Elizabeth J Hovey, Helen Wheeler
BACKGROUND: Bevacizumab has been associated with prolonged progression-free survival for patients with recurrent glioblastoma; however, not all derive a benefit. An early indicator of efficacy or futility may allow early discontinuation for nonresponders. This study prospectively assessed the role of early magnetic resonance imaging (eMRI) and its correlation with subsequent routine magnetic resonance imaging (MRI) results and survival. METHODS: Patients were part of a randomized phase 2 clinical trial (CABARET) comparing bevacizumab with bevacizumab plus carboplatin for recurrent glioblastoma...
July 5, 2017: Cancer
https://www.readbyqxmd.com/read/28668888/efficacy-of-combination-therapy-with-met-and-vegf-inhibitors-for-met-overexpressing-glioblastoma
#16
Takeshi Okuda, Takayuki Tasaki, Susumu Nakata, Kimihiro Yamashita, Hiromasa Yoshioka, Shuichi Izumoto, Amami Kato, Mitsugu Fujita
BACKGROUND: Glioblastoma multiforme (GBM) is a malignant brain tumor with an extremely poor prognosis. GBM tissues frequently express mesenchymal-epithelial transition factor (MET), which induces cell division, growth and migration. In addition, angiogenesis is a significant feature of GBM, attributable to the overexpression of vascular endothelial growth factor (VEGF). Although the VEGF inhibitor bevacizumab was recently highlighted as the second-line drug for GBM treatment, GBMs often recur even with bevacizumab therapy...
July 2017: Anticancer Research
https://www.readbyqxmd.com/read/28667595/optimizing-bevacizumab-dosing-in-glioblastoma-less-is-more
#17
Abdulrazag Ajlan, Piia Thomas, Abdulrahman Albakr, Seema Nagpal, Lawrence Recht
Compared to traditional chemotherapies, where dose limiting toxicities represent the maximum possible dose, monoclonal antibody therapies are used at doses well below maximum tolerated dose. However, there has been little effort to ascertain whether there is a submaximal dose at which the efficacy/complication ratio is maximized. Thus, despite the general practice of using Bevacizumab (BEV) at dosages of 10 mg/kg every other week for glioma patients, there has not been much prior work examining whether the relatively high complication rates reported with this agent can be decreased by lowering the dose without impairing efficacy...
June 30, 2017: Journal of Neuro-oncology
https://www.readbyqxmd.com/read/28660172/pineal-region-glioblastoma-a-case-report-and-literature-review
#18
Hayley Beacher Stowe, C Ryan Miller, Jing Wu, Dina M Randazzo, Andrew Wenhua Ju
INTRODUCTION: Pineal region glioblastoma multiforme (GBM) is a rare disease entity with a generally poor prognosis. We present a case of a patient with an unresectable pineal region GBM treated with chemoradiation with favorable outcome. CASE BACKGROUND: A 65-year-old patient who was presented with visual symptoms was found to have a pineal region tumor on imaging. A stereotactic biopsy showed a World Health Organization Grade IV GBM, O-6-methylguanine-DNA methyltransferase (MGMT) promoter methylated, isocitrate dehydrogenase 1 and 2 wild type...
2017: Frontiers in Oncology
https://www.readbyqxmd.com/read/28655794/diffusion-mri-phenotypes-predict-overall-survival-benefitfrom-anti-vegf-monotherapy-in-recurrent-glioblastoma-converging-evidence-from-phase-ii-trials
#19
Benjamin M Ellingson, Elizabeth Gerstner, Marion Smits, Raymond Y Huang, Rivka R Colen, Lauren E Abrey, Dana T Aftab, Gisela M Schwab, Colin Hessel, Robert J Harris, Ararat Chakhoyan, Renske Gahrmann, Whitney B Pope, Kevin Leu, Catalina Raymond, Davis C Woodworth, John F de Groot, Patrick Y Wen, Tracy Batchelor, Martin J van den Bent, Timothy F Cloughesy
Anti-VEGF therapies remain controversial in the treatment of recurrent glioblastoma (GBM). In the current study we demonstrate that recurrent GBM patients with a specific diffusion MR imaging signature have an overall survival (OS) advantage when treated with cediranib, bevacizumab, cabozantinib, or aflibercept monotherapy at first or second recurrence. These findings were validated using a separate trial comparing bevacizumab with lomustine. <br /><br />Experimental Design: Patients with recurrent GBM and diffusion MRI from the monotherapy arms of 5 separate Phase II clinical trials were included: 1) cediranib (NCT00035656); 2) bevacizumab (BRAIN Trial, AVF3708g; NCT00345163); 3) cabozantinib (XL184-201; NCT00704288); 4) aflibercept (VEGF Trap; NCT00369590); and 5) bevacizumab or lomustine (BELOB; NTR1929)...
June 27, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/28638456/temozolomide-and-bevacizumab-induction-before-chemoradiotherapy-in-patients-with-bulky-glioblastoma-and-or-with-severe-neurological-impairment
#20
Ilan Darmon, Mony Chenda Morisse, Alexandre Coutte, Marie Blonski, Emilie Le Rhun, Luc Taillandier, Diana Bello Roufai, Christine Desenclos, Stéphanie Trudel, Jean-Christophe Faivre, Nicolas Blanchard, Bruno Chauffert, Mathieu Boone
Background. New approaches are needed for patients newly diagnosed with bulky glioblastoma (GB) and/or with severe neurological impairment that cannot benefit from first line temozolomide (TMZ)-based chemoradiotherapy. Bevacizumab (BEV), an antiangiogenic anti-VEGF-R monoclonal antibody, has a rapid impact on tumor-related brain edema in recurrent GB. The present study reports the feasibility and efficacy of an induction treatment with TMZ and BEV to alleviate the initial neurological impairment and/or to reduce the tumor volume before a delayed chemoradiotherapy...
2017: Journal of Cancer
keyword
keyword
80321
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"